David T. Severson

Activation of FcγR and classical complement pathways contribute to T-DXd plus pertuzumab therapeutic efficacy

In addition to delivering cytotoxic payloads, HER2-targeted antibody–drug conjugates (ADCs) can engage innate immune effector pathways (such as FcγR and complement) similar to monoclonal antibodies (mAbs). However, the relative contribution of innate pathways to therapeutic benef...